This is probably the better benchmark for this trial, notwithstanding that it will be the depth of response (the durability) that will be the point of difference that CORE NK is expected to add. This is a quick summary that Grok puts forth:
Ann: ADVENT-AML Phase 1B clinical trial update, page-30
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.99M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $949 | 312.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 67782438 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 91927011 | 27 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |